We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Edasalonexent

News List

Catabasis, Duchenne UK announce partnership to evaluate edasalonexent in phase 2 non-ambulatory DMD trial pharmaceutical-business-review
January 13, 2020
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for ...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent foodmate
September 27, 2018
Catabasis announced the initiation of PolarisDMD, the company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD). Edasalonexent inhibits NF-kB, which is the key link between loss of dystrophin and disease pathology and plays a fundamen